Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brazil approves PHC’s protein technology

Brazil has approved the sale and use of the US-based, UK-listed bioproducts company, Plant Health Care’s (PHC), proprietary harpin protein technology for foliar application on all crops. The approval marks the first product registration in Brazil from the Ministry of Agriculture, the company notes. Arysta LifeScience has entered into a development and distribution agreement with PHC for foliar applications on sugar cane in the country. PHC says that it will invoke that deal. Arysta agreed to evaluate the current protein technology across a range of geographical locations throughout Brazil and generate detailed data on increased biomass and sucrose production. Results have been positive, and pending consistent and reliable test results in the evaluation programme, first sales of the product in Brazil are anticipated in the 2017 crop season. The technology is approved for usage in 12 countries, including the US.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG022729

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel